<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress/2.3.2" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>

<channel>
	<title>Smart Information About Acne</title>
	<link>http://acne-and-you.com</link>
	<description>Research Info About Your Acne Issues</description>
	<pubDate>Tue, 19 Aug 2008 22:08:45 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.3.2</generator>
	<language>en</language>
			<item>
		<title>Funding For Clinical Trials For New Probe To Detect Skin Cancer</title>
		<link>http://acne-and-you.com//funding-for-clinical-trials-for-new-probe-to-detect-skin-cancer</link>
		<comments>http://acne-and-you.com//funding-for-clinical-trials-for-new-probe-to-detect-skin-cancer#comments</comments>
		<pubDate>Tue, 19 Aug 2008 22:08:45 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[Assistant Professor James Tunnell has been awarded a Phase II Early Career Award from the Wallace H. Coulter Foundation to continue the development and testing of a device that uses light to detect skin cancer without the need for an invasive biopsy procedure.    The $260,000 grant will support Tunnell&#8217;s work for the [...]]]></description>
			<content:encoded><![CDATA[<p>Assistant Professor James Tunnell has been awarded a Phase II Early Career Award from the Wallace H. Coulter Foundation to continue the development and testing of a device that uses light to detect skin cancer without the need for an invasive biopsy procedure.    The $260,000 grant will support Tunnell&#8217;s work for the next two years to refine the device called a &#8220;clinical spectrometer&#8221; and to conduct additional clinical trials.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118649.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//funding-for-clinical-trials-for-new-probe-to-detect-skin-cancer/feed</wfw:commentRss>
		</item>
		<item>
		<title>Study Of Hair Dynamics May Lead To Better Hair-Care Products</title>
		<link>http://acne-and-you.com//study-of-hair-dynamics-may-lead-to-better-hair-care-products</link>
		<comments>http://acne-and-you.com//study-of-hair-dynamics-may-lead-to-better-hair-care-products#comments</comments>
		<pubDate>Mon, 18 Aug 2008 22:08:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[From frizzy perms to over-bleached waves, &#8220;bad hair days&#8221; could soon become a less frequent occurrence. Chemists report the first detailed microscopic analysis of what happens to individual hair fibers when they interact with each other, an advance in knowledge key to the development of improved shampoos, conditioners, and other products for repairing damaged hair, [...]]]></description>
			<content:encoded><![CDATA[<p>From frizzy perms to over-bleached waves, &#8220;bad hair days&#8221; could soon become a less frequent occurrence. Chemists report the first detailed microscopic analysis of what happens to individual hair fibers when they interact with each other, an advance in knowledge key to the development of improved shampoos, conditioners, and other products for repairing damaged hair, the researchers say. They presented the study at the American Chemical Society&#8217;s 236th National Meeting.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118533.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//study-of-hair-dynamics-may-lead-to-better-hair-care-products/feed</wfw:commentRss>
		</item>
		<item>
		<title>ImmuneRegen(R) BioSciences Confirms Homspera(R) Advances Wound Healing In Topical Application</title>
		<link>http://acne-and-you.com//immuneregenr-biosciences-confirms-homsperar-advances-wound-healing-in-topical-application</link>
		<comments>http://acne-and-you.com//immuneregenr-biosciences-confirms-homsperar-advances-wound-healing-in-topical-application#comments</comments>
		<pubDate>Mon, 18 Aug 2008 22:08:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug candidate, Homspera®, has accelerated the healing process of deep, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc., a biotechnology development company that also provides contracted [...]]]></description>
			<content:encoded><![CDATA[<p>ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug candidate, Homspera®, has accelerated the healing process of deep, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc., a biotechnology development company that also provides contracted preclinical research services.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118500.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//immuneregenr-biosciences-confirms-homsperar-advances-wound-healing-in-topical-application/feed</wfw:commentRss>
		</item>
		<item>
		<title>Nomir Medical To Present Positive Onychomycosis Data For Its Noveon(R) Dual Wavelength Device</title>
		<link>http://acne-and-you.com//nomir-medical-to-present-positive-onychomycosis-data-for-its-noveonr-dual-wavelength-device</link>
		<comments>http://acne-and-you.com//nomir-medical-to-present-positive-onychomycosis-data-for-its-noveonr-dual-wavelength-device#comments</comments>
		<pubDate>Mon, 18 Aug 2008 21:08:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[Nomir Medical Technologies, a leader in the development of optical energy technologies for anti-infective medical applications, announced that the Company will present an abstract detailing positive in vitro and in vivo human data from its study of onychomycosis (toe nail fungus) using Noveon®, a novel dual wavelength optical energy device.
More:  continued here 
]]></description>
			<content:encoded><![CDATA[<p>Nomir Medical Technologies, a leader in the development of optical energy technologies for anti-infective medical applications, announced that the Company will present an abstract detailing positive in vitro and in vivo human data from its study of onychomycosis (toe nail fungus) using Noveon®, a novel dual wavelength optical energy device.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118511.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//nomir-medical-to-present-positive-onychomycosis-data-for-its-noveonr-dual-wavelength-device/feed</wfw:commentRss>
		</item>
		<item>
		<title>Leishmaniasis Parasites Evade Death By Exploiting The Immune Response To Sand Fly Bites</title>
		<link>http://acne-and-you.com//leishmaniasis-parasites-evade-death-by-exploiting-the-immune-response-to-sand-fly-bites</link>
		<comments>http://acne-and-you.com//leishmaniasis-parasites-evade-death-by-exploiting-the-immune-response-to-sand-fly-bites#comments</comments>
		<pubDate>Sun, 17 Aug 2008 22:08:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[  Cutaneous leishmaniasis, a disease characterized by painful skin ulcers, occurs when the parasite Leishmania major, or a related species, is transmitted to a mammalian host by the bite of an infected sand fly. In a new study from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of [...]]]></description>
			<content:encoded><![CDATA[<p>  Cutaneous leishmaniasis, a disease characterized by painful skin ulcers, occurs when the parasite Leishmania major, or a related species, is transmitted to a mammalian host by the bite of an infected sand fly. In a new study from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, scientists have discovered L.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118380.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//leishmaniasis-parasites-evade-death-by-exploiting-the-immune-response-to-sand-fly-bites/feed</wfw:commentRss>
		</item>
		<item>
		<title>Prototype Test For Predicting Clinical Outcome For Melanoma Patients - Gene Signature Prognostication Of Rapid Progression From Stage III To Stage IV</title>
		<link>http://acne-and-you.com//prototype-test-for-predicting-clinical-outcome-for-melanoma-patients-gene-signature-prognostication-of-rapid-progression-from-stage-iii-to-stage-iv</link>
		<comments>http://acne-and-you.com//prototype-test-for-predicting-clinical-outcome-for-melanoma-patients-gene-signature-prognostication-of-rapid-progression-from-stage-iii-to-stage-iv#comments</comments>
		<pubDate>Sat, 16 Aug 2008 22:08:54 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.
More:  continued here 
]]></description>
			<content:encoded><![CDATA[<p>Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118347.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//prototype-test-for-predicting-clinical-outcome-for-melanoma-patients-gene-signature-prognostication-of-rapid-progression-from-stage-iii-to-stage-iv/feed</wfw:commentRss>
		</item>
		<item>
		<title>Society Of Permanent Cosmetic Professionals To Host European Training Event In Brussels</title>
		<link>http://acne-and-you.com//society-of-permanent-cosmetic-professionals-to-host-european-training-event-in-brussels</link>
		<comments>http://acne-and-you.com//society-of-permanent-cosmetic-professionals-to-host-european-training-event-in-brussels#comments</comments>
		<pubDate>Thu, 14 Aug 2008 21:08:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[ The Society of Permanent Cosmetic Professionals (SPCP) is conducting its first European Workshop, which will be held in Brussels, Belgium October 12-14, 2008. This groundbreaking event is being held in consideration of hundreds of International SPCP members. The SPCP values and appreciates the support and attendance put forth by its European members at annual [...]]]></description>
			<content:encoded><![CDATA[<p> The Society of Permanent Cosmetic Professionals (SPCP) is conducting its first European Workshop, which will be held in Brussels, Belgium October 12-14, 2008. This groundbreaking event is being held in consideration of hundreds of International SPCP members. The SPCP values and appreciates the support and attendance put forth by its European members at annual SPCP events in the U.S.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118238.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//society-of-permanent-cosmetic-professionals-to-host-european-training-event-in-brussels/feed</wfw:commentRss>
		</item>
		<item>
		<title>Murad Awarded Skin Cancer Foundation Seals Of Approval For Two Products</title>
		<link>http://acne-and-you.com//murad-awarded-skin-cancer-foundation-seals-of-approval-for-two-products</link>
		<comments>http://acne-and-you.com//murad-awarded-skin-cancer-foundation-seals-of-approval-for-two-products#comments</comments>
		<pubDate>Thu, 14 Aug 2008 23:08:58 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[Murad announced that it has received two seals of approval from the Skin Cancer Foundation. Two products - Murad Professional Daily Moisture Charge SPF 30 and Murad Man Face Defense SPF 15 - have completed a vigorous review process and are now recommended for sun safety and approved by the Skin Cancer Foundation.
More:  continued [...]]]></description>
			<content:encoded><![CDATA[<p>Murad announced that it has received two seals of approval from the Skin Cancer Foundation. Two products - Murad Professional Daily Moisture Charge SPF 30 and Murad Man Face Defense SPF 15 - have completed a vigorous review process and are now recommended for sun safety and approved by the Skin Cancer Foundation.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118174.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//murad-awarded-skin-cancer-foundation-seals-of-approval-for-two-products/feed</wfw:commentRss>
		</item>
		<item>
		<title>Moisturisers Increased Non-Melanoma Skin Cancers In Mice</title>
		<link>http://acne-and-you.com//moisturisers-increased-non-melanoma-skin-cancers-in-mice</link>
		<comments>http://acne-and-you.com//moisturisers-increased-non-melanoma-skin-cancers-in-mice#comments</comments>
		<pubDate>Thu, 14 Aug 2008 20:08:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[  Researchers in the US found that several moisturisers commonly used by consumers increased non-melanoma skin cancers in mice that had     been exposed to ultra violet radiation.    The study is published  in the 14 Aug 2008 advanced online issue of the Journal of Investigative Dermatology and [...]]]></description>
			<content:encoded><![CDATA[<p>  Researchers in the US found that several moisturisers commonly used by consumers increased non-melanoma skin cancers in mice that had     been exposed to ultra violet radiation.    The study is published  in the 14 Aug 2008 advanced online issue of the Journal of Investigative Dermatology and was the work of Dr Allan     Conney and colleagues from the Susan Lehman Cullman Laboratory for Cancer Research at the University of New Jersey.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118308.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//moisturisers-increased-non-melanoma-skin-cancers-in-mice/feed</wfw:commentRss>
		</item>
		<item>
		<title>Oxygen Biotherapeutics Develops Gel Version Of Oxycyte(R) For Treating Surface Wounds</title>
		<link>http://acne-and-you.com//oxygen-biotherapeutics-develops-gel-version-of-oxycyter-for-treating-surface-wounds</link>
		<comments>http://acne-and-you.com//oxygen-biotherapeutics-develops-gel-version-of-oxycyter-for-treating-surface-wounds#comments</comments>
		<pubDate>Wed, 13 Aug 2008 20:08:58 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<guid isPermaLink="false"></guid>
		<description><![CDATA[Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company has developed a gel-like form of Oxycyte® that it intends to investigate as a topical application for open wounds, abrasions and burns. Oxycyte is the Company&#8217;s perfluorocarbon (PFC) therapeutic oxygen carrier.   The innovation is based on technologies in-licensed earlier this year from Virginia Commonwealth University.
More: [...]]]></description>
			<content:encoded><![CDATA[<p>Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company has developed a gel-like form of Oxycyte® that it intends to investigate as a topical application for open wounds, abrasions and burns. Oxycyte is the Company&#8217;s perfluorocarbon (PFC) therapeutic oxygen carrier.   The innovation is based on technologies in-licensed earlier this year from Virginia Commonwealth University.</p>
<p><b>More:</b> <a target='_blank' href='http://www.medicalnewstoday.com/articles/118027.php'> continued here </a></p>
]]></content:encoded>
			<wfw:commentRss>http://acne-and-you.com//oxygen-biotherapeutics-develops-gel-version-of-oxycyter-for-treating-surface-wounds/feed</wfw:commentRss>
		</item>
	</channel>
</rss>
